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Abstract 
In the last years, the use of probiotics, including Lactobacillus species, has received much attention to prevent and 
treat vaginal disorders. These species have been described as having the ability to colonize the epithelial surface and 
produce antimicrobial metabolites that are able to control the remaining vaginal microflora. This study aimed to iden‑
tify and characterize, for the first time, a bacteriocin natively produced by Lactobacillus acidophilus KS400 (probiotic 
strain from  Gynoflor®‑Medinova AG, Switzerland) and its antimicrobial activity against relevant urogenital pathogens. 
After organic acids and hydrogen peroxide neutralization in the fermented Lactobacillus acidophilus KS400 culture 
medium, bacteriocin activity was tested against the indicator microorganism Lactobacillus delbrueckii ATCC9649. The 
fermentation of Lactobacillus acidophilus KS400 for bacteriocin production was carried out in batch mode, and its anti‑
microbial activity, optical density and pH were monitored. After production and extraction, the bacteriocin molecular 
weight was estimated by electrophoresis and tested against vaginal pathogenic microorganisms. As described for 
other bacteriocins, batch fermentation profiles indicated that bacteriocin production occurs during the exponential 
growth phase of the lactobacilli, and declines during their stationary growth phase. The molecular weight of the 
bacteriocin is approximately 7.5 kDa. The bacteriocin containing protein extract was shown to inhibit the growth of 
Gardnerella vaginalis, Streptococcus agalactiae, Pseudomonas aeruginosa and the indicator strain Lactobacillus del-
brueckii ATCC9649. We conclude that L. acidophilus KS400 produces bacteriocin with antimicrobial activity against 
relevant urogenital pathogens.
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Introduction
The term probiotic was derived from the Greek ‘biotikos’, 
meaning “for life” and refers to “live microorganisms 
which when administered in adequate amounts confer a 
health benefit on the host” (FAO 2006). In last three dec-
ades, the use of probiotics has received much attention 
as a treatment and prevention option for vaginal disor-
ders (Barrons and Tassone 2008; Coudeyras et  al. 2009; 
Homayouni et  al. 2014). The equilibrium between the 
several microorganisms that compose the human vaginal 
microflora is important for the maintenance of its home-
ostasis, affecting directly the health status of woman 
(Gajer et al. 2012; Ravel et al. 2011). Among the prevalent 
microorganisms, the Lactobacillus species represent at 
least 70%  (107–108 CFU (colony forming units)/g of vagi-
nal fluid) of the bacteria identified in the reproductive 
system of healthy premenopausal women (Anukam et al. 
2006; Ravel et al. 2011; Strus et al. 2005; Zhou et al. 2004). 
The most prevalent Lactobacillus spp. in the vagina are 
L. crispatus, L. jensenii, L. gasseri and L. iners (Pavlova 
et al. 2002; Vásquez et al. 2002; Zhou et al. 2010). In the 
vaginal epithelium, Lactobacillus induce probiosis in two 
stages: (1) colonizing the epithelial surface, competing for 
attachment sites and promote pathogen co-aggregation 
(competitive exclusion) (Coudeyras et  al. 2009; Martín 
et al. 2012; Zárate and Nader‐Macias 2006); and (2) pro-
ducing antimicrobial metabolite substances that are able 
to control the remaining vaginal microflora (microbial 
killing, inhibition) (Heng-Yi et al. 2008; Kaewsrichan et al. 
2006; Voravuthikunchai et al. 2006). Within the different 
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metabolites produced by Lactobacillus, organic acids 
(mainly lactic acid) and hydrogen peroxide are respon-
sible for broad-spectrum microbial inhibitory effect 
(O’Hanlon et al. 2013; Tomás et al. 2003). On top of this, 
production of more specific antimicrobial proteins (bac-
teriocins) have been described (Aroutcheva et  al. 2001; 
Pingitore et al. 2009; Turovskiy et al. 2009). Bacteriocins 
are molecules with proteinaceous nature which have bac-
tericidal or bacteriostatic activity against closely related 
species (narrow spectrum) or across genera (broad 
spectrum) (Cotter et  al. 2005; Klaenhammer 1993). 
Gram-positive bacteria, especially lactic acid bacteria 
(lactobacilli, lactococci and pediococci), produce these 
antimicrobial peptides and proteins in the ribosomes, 
such as lactacin B from Lactobacillus acidophilus (Bare-
foot and Klaenhammer 1983; Muriana and Klaenham-
mer 1991), plantaricin 423 from Lactobacillus plantarum 
(Van Reenen et al. 1998), pediocin ST18 from Pediococ-
cus pentosaceus (Todorov and Dicks 2005), nisin Q from 
Lactococcus lactis (Zendo et  al. 2003) and several oth-
ers from other bacteria (Netz et al. 2002; Srionnual et al. 
2007). Due all above characteristics, Lactobacillus species 
have been proposed as vaginal probiotic and used for the 
reestablishment of the vaginal environment balance, pre-
venting growth of pathogens in the vagina (Kaewsrichan 
et al. 2006; Zárate and Nader‐Macias 2006). The safe use 
of Lactobacillus species as probiotic agents in human 
vagina dates back to 1915 (Newman 1915). In this in vitro 
study, we evaluated whether Lactobacillus acidophilus 
KS400 (LaKS400,  Gynoflor®, Medinova AG, Switzerland) 
is a bacteriocin producer and its antimicrobial activity.
Materials and methods
Microorganism strains
The bacterial and fungal strains used in this study, includ-
ing the investigated strain (LaKS400), the bioactivity 
indicator strain (Lactobacillus delbrueckii ATCC9649) 
and urogenital pathogens selected to assess the protein 
antimicrobial activity are shown in Table  1. Bacterial 
and fungal strains suspended in adequate medium added 
with 25% of glycerol (VWR, Spain) and stored frozen at 
− 80 °C, until used.
When gelose medium was required (for example, for 
the maintenance of microorganisms), bacteriological 
agar (VWR, Spain) was added to the liquid medium at 
the final concentration of 20  g/L. De Man, Rogosa and 
Sharpe (MRS) soft agar was prepared with 7.5 g/L bacte-
riological agar.
Bacteriocin detection
LaKS400 was cultivated in 10  mL MRS broth (VWR, 
Spain) pH 6.5 for 24  h at 37  °C in the presence of 10% 
 CO2. After incubation, the cell culture was heated at 
70  °C for 30  min to assure inhibition of protease activ-
ity, then cooled at room temperature and centrifuged 
(4500 rpm for 15 min at 4 °C) with a benchtop centrifuge 
(Heraeus megafuge 8R centrifuge, Thermo-fisher Scien-
tific, EUA). In order to eliminate the antimicrobial effect 
of organic acids, the pH of the supernatants was adjusted 
to 6.5 with 10 M NaOH solution. The inhibitory activity 
from hydrogen peroxide was eliminated by the addition 
of 5  mg/mL catalase from bovine liver (Sigma-Aldrich, 
EUA) followed by filtration through a 0.2  µm pore-size 
cellulose acetate (Fisher-Scientific, UK).
Bacteriocin detection was performed by using a modifi-
cation of the antagonist well-diffusion method described 
Table 1 Bacterial and fungal strains used in this study
a Indicator microorganism
Microorganisms Source Growth condition 
(media, temperature 
and atmosphere)
Lactobacillus acidophilus KS400 Medinova MRSB, 37 °C, 10%  CO2
Lactobacillus delbrueckii  ATCC9649a ATCC collection MRSB, 37 °C, 10%  CO2
Gardnerella vaginalis 586876 Clinical NYCIIIB, 37 °C, 10%  CO2
Gardnerella vaginalis 563765 Clinical NYCIIIB, 37 °C, 10%  CO2
Gardnerella vaginalis 568799 Clinical NYCIIIB, 37 °C, 10%  CO2
Staphylococcus aureus ATCC6538 Collection TSB, 37 °C, aerobic
Streptococcus agalactiae 181324 Clinical BHIB, 37 °C, aerobic
Streptococcus agalactiae 179954 Clinical BHIB, 37 °C, aerobic
Pseudomonas aeruginosa ATCC15442 Collection TSB, 37 °C, aerobic
Escherichia coli ATCC8739 Collection TSB, 37 °C, aerobic
Candida albicans ATCC10231 Collection BHIB, 37 °C, aerobic
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by Tagg and McGiven (1971): briefly, 20 mL of MRS soft 
agar was inoculated with 200 µl of the indicator microor-
ganism (Lactobacillus delbrueckii ATCC9649) in an over-
night culture. Wells with 4 mm diameter were punched 
in agar plates and filled with 100  µl of cell-free culture 
supernatants. Phosphate-buffered saline (PBS) was used 
as negative control. The plates were maintained at room 
temperature for 3 h to allow for bacteriocin diffusion, fol-
lowed by incubation at 37 °C in the presence of 10%  CO2, 
during 24–48 h. The bacteriocin activity was determined 
by macroscopic observation of a clear inhibition zone on 
the agar.
Bacteriocin production
To study the bacteriocin production kinetics, 500  mL 
of MRS broth at pH 6.5 were inoculated with LaKS400 
strain (1% v/v) and incubated at 37 °C in the presence of 
gaseous nitrogen without agitation. At every hour during 
fermentation, both bacterial cell density and the culture 
medium pH were measured. Every 2 h we proceeded to 
the evaluation of antimicrobial activity against the indi-
cator strain (Lactobacillus delbrueckii ATCC9649) as 
described above.
For bacteriocin production, a 20 h old culture (10 mL) 
of LaKS400 was inoculated (1% v/v) in 1 L of MRS broth. 
Batch fermentation was performed at 37  °C, without 
agitation, in the presence of nitrogen for 24 h. This pro-
cedure ensures an interruption of the bacterial growth 
prior to the stationary phase. Thus, it is prevented that 
proteases released into the extracellular medium degrade 
the bacteriocin.
Preparation of bacteriocin extracts
Bacteriocin extracts were prepared according to the 
method described by Yang et al. (1992) with some modi-
fications. Briefly, 1  L of culture medium from LaKS400 
cells fermentation was adjusted to pH 6.5 with 1  M 
NaOH solution followed by stirring at room temperature 
for 30  min, in order to allow the adsorption of bacteri-
ocin to the producer cells. Then, the culture was heated 
at 70  °C for 30  min. Bacterial cells were harvested by 
benchtop centrifuge (Heraeus megafuge 8R centrifuge, 
Thermo-fisher Scientific, EUA) at 4500  rpm for 15  min 
at 4  °C and then were washed twice with 5 mM sodium 
phosphate (pH 6.5) and harvested by centrifugation in the 
same conditions. Then, bacterial cells were resuspended 
in 50 mL of 100 mM NaCl at pH 2.0 (adjusted with 5% 
phosphoric acid) and mixed with a magnetic stirrer for 
1 h at 4  °C. The cell suspension was then centrifuged at 
4500  rpm for 15  min at 4  °C and cell-free supernatant 
adjusted to pH 6.5 with 1 M NaOH solution. Bacteriocin 
extract obtained was filtrated through a 0.2 µm pore-size 
cellulose acetate (Fisher Scientific, UK) and the bioactiv-
ity was tested as previously described.
Electrophoresis
As 1D protein electrophoresis (separation in one dimen-
sion) allows to separate biomolecules based on their size 
and structure, bacteriocin extract that exhibited bio-
activity against the indicator strain was subjected to an 
electrophoresis in Tricine-SDS-PAGE on Bio-Rad Mini 
Protean 3 Cell apparatus (Bio-rad, USA). 4% polyacryla-
mide was used in the stacking gel and 16% polyacryla-
mide in the separation gel, as described by Schägger 
(2006). This procedure was made in duplicate. A 25  μL 
of bacteriocin sample was mixed with 25  μL of twofold 
concentrated buffer (Tris base 100 mM, glycine 100 mM, 
SDS 4%, urea 8 M, bromophenol blue 0.01%) and heated 
for 5 min at 100 °C. NZYColour Protein Marker II (NZY-
Tech, Portugal), was used as molecular weight marker, 
with sizes ranging from 11 to 245  kDa. Electrophoresis 
was run at constant 35 mA for stacking gel and 50 mA for 
resolution gel.
In order to identify the position of the active bacte-
riocin, one half of the gel was fixed with methanol and 
acetic acid and washed three times with 250  mL of 
MiliQ Water for no longer than 30 min. The gel was then 
placed in a sterile petri dish and overlaid with MRS soft 
agar medium with 1% Lactobacillus delbrueckii ATCC 
9649. The active bacteriocin was detected by macro-
scopic observation of an inhibition halo, after incubat-
ing at 37  °C, during 48  h in the presence of  CO2 10%. 
The other half of the gel was observed and photo-doc-
umented in Bio-Rad ChemiDoc MP in stain free mode. 
In addition, the influence of β-mercaptoethanol, on the 
bacteriocin antimicrobial activity was tested in order to 
confirm if the active protein had disulfide bridges. In fact 
β-mercaptoethanol is described as being responsible for 
the loss of the bacteriocin antimicrobial activity (Aslam 
et al. 2011; Deraz et al. 2007).
Antimicrobial activity
The bacteriocin antimicrobial activity was assessed 
following the microdilution method as described else-
where (Rex et  al. 2008; Standards 2006). Briefly, wells 
from a microplate were filled with 100 μL of bacteriocin 
extract prepared as described previously and 100  μL 
of pathogen suspension in culture medium (contain-
ing 1 × 105 cells assessed by optical density). Negative 
controls were performed corresponding to bacteri-
ocin extract in sterile culture medium (2 wells for each 
type of culture medium used to support the pathogens 
growth); positive controls corresponded to 100  μL of 
Page 4 of 8Gaspar et al. AMB Expr  (2018) 8:153 
pathogen suspension and 100  μL of PBS replacing the 
bacteriocin extract. The microplate was incubated at 
optimal growth conditions for the enrolled pathogens. 
After incubation, the presence or absence of patho-
gen growth in each well was compared to the growth 
obtained in the positive control. For this assay the 




The antimicrobial activity of the bacteriocin produced 
by LaKS400, obtained from the filtered culture medium 
after organic acids and hydrogen peroxide neutralization, 
showed a clear inhibition zone in agar when compared 
with negative control (PBS) (no inhibition observed), 
using Lactobacillus delbrueckii ATCC9649 as indicator 
organism (Fig. 1).
Bacteriocin production and metabolites kinetic
The organic acids produced by Lactobacillus (con-
sequent to carbohydrates fermentation) induce a pH 
decrease of the medium. Batch-fermentation approach 
confirms a decrease in pH resulting from organic acid 
accumulation in the extracellular medium (Fig. 2, yel-
low line). After 36 h of LaKS400 fermentation the pH 
value was 4.3. In this study, the antimicrobial effect of 
organic acids was neutralized by the addition of a base 
solution, in order to eliminate its possible influence 
in the antimicrobial assessment of the bacteriocin. In 
addition, we have also considered that during batch 
fermentation included in our procedure, some amount 
of hydrogen peroxide could have been produced, thus 
S1 PBS1X
Fig. 1 Antimicrobial activity of Lactobacillus acidophilus KS400 
bacteriocin against Lactobacillus delbrueckii ATCC9649. Culture 
extracts of Lactobacillus acidophilus KS400 tested by the agar well 
diffusion method described (Tagg and McGiven 1971). S1—culture 
medium from Lactobacillus acidophilus KS400 medium; PBS 1X—
negative control corresponding to ×1 phosphate buffered saline
Fig. 2 a Batch fermentation of Lactobacillus acidophilus KS400 strain in MRSB with non‑controlled pH (initial value of 6.5) at 37 °C. Left axis: 
absorvance (Abs) at 600 nm; Primary right axis: pH values; Secondary right axis: Relative bacteriocin activity (%); Bottom axis: Time (hours). 
Symbols:  Optical density at 600 nm;  Changes in pH values; (‑grey bars‑) Bacteriocin activity production. b Antimicrobial activity of Lactobacillus 
acidophilus KS400 strain during fermentation; Activity was tested against Lactobacillus delbrueckii ATCC9649 and plates were incubated at 37 °C; 10% 
 CO2
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we proceeded to its catalysation by adding catalase to 
the medium after the fermentation was completed. 
Thus, the relative bacteriocin activity was determined 
in relation to the sample that showed highest bioac-
tivity (at time 30  h). The batch fermentation profiles 
of LaKS400 indicated that the bacteriocin produc-
tion was more evident and clearly increased during 
the exponential growth phase, followed by a reduc-
tion during the stationary growth phase, as shown in 
Fig. 2a (grey bars).
After 32 h of fermentation a loss on the bacteriocin 
antimicrobial activity was observed (Fig.  2), by halo 
inhibition decrease.
Bacteriocin molecular weight
Proteins were separated and a bioactivity assay was 
carried out with an indicator strain (Lactobacillus 
delbrueckii ATCC9649) directly on gel electropho-
resis (Fig.  3b), in order to identify the active protein. 
Tricine-SDS-PAGE gel extraction of proteins resulted 
in a single zone of growth inhibition when the gel 
was overlaid with the indicator strain (Fig. 3). Adding 
β-mercaptoethanol did not influence the bacteriocin 
antimicrobial activity (+ β in Fig. 3).
The protein exhibiting antimicrobial activity in the 
electrophoresis gel corresponded to a band with an 
estimated molecular weight of approximately 7.5 kDa, 
considering that bioactivity and bacteriocin band was 
observed below to the 11 kD marker protein.
Bacteriocin activity against pathogenic strains
The LaKS400 bacteriocin extract was tested against the 
indicator strain, pathogenic bacteria (including collection 
and clinical isolates) and Candida albicans ATCC10231 
as shown in Table 2.
The bacteriocin extract was shown to inhibit the 
growth of the indicator strain Lactobacillus delbrueckii 
ATCC9649, Gardnerella vaginalis, Streptococcus aga-
lactiae and Pseudomonas aeruginosa. No antimicrobial 
effect was observed against the enrolled strains of Escher-
ichia coli, Staphylococcus aureus and Candida albicans.
Discussion
This study aimed to evaluate the ability of LaKS400 to 
produce bacteriocin with antimicrobial activity against 
urogenital pathogens, expressing mechanism of action 
that was not previously reported in other in vitro studies 
performed for this strain (Ünlü and Donders 2011).
The bacteriocin production and detection was per-
formed in  vitro and accompanied by the production 
of other bacterial metabolites (such as lactic acid and 
hydrogen peroxide) that were previously described for 
this strain. Thus, to assure that the bioactivity assessed 
for the protein extract was not related to these metabo-
lites, their effect was neutralized. Thus, the experimental 
results suggest that a proteinaceous antimicrobial com-
pound, bacteriocin, had been produced and secreted by 
LaKS400 into the extracellular culture medium. The bac-
teriocin production occurs during the exponential phase 
reaching its maximum during the stationary phase of the 
strain growth curve (between 24 and 30 h after the start 
Fig. 3 Direct detection of antimicrobial activity of Lactobacillus acidophilus KS400 bacteriocin (A) Tricine‑SDS‑PAGE gel was observed in ChemiDoc™ 
MP System (Biorad) using the stain free function for protein gels: (MW) molecular mass protein standards (NZYTECH, Portugal); − β/+ β—absence 
and presence of β‑mercaptoethanol (B) Zone of growth inhibition corresponding to the position of the antimicrobial protein (bacteriocin)
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of fermentation), as described for other bacteriocins (De 
Vuyst et al. 1996; De Vuyst and Vandamme 1992; Zamfir 
et al. 2000). However, after 32 h of fermentation a loss on 
the bacteriocin antimicrobial activity was observed. This 
change in the bioactivity can be related to protein aggre-
gation or proteolytic degradation of the bacteriocin (Law 
and Kolstad 1983).
Based on the described results we conclude that 
LaKS400 produces a bacteriocin with an expected size 
of 7.5 kDa. This molecular weight is within the range of 
the most frequently reported bacteriocins from Lacto-
bacillus spp. (Vuyst and Vandamme 1994). In fact, for 
Lactobacillus acidophilus, the size described for bacte-
riocins ranges from 2.5 to 100 kda (Barefoot and Klaen-
hammer 1983; Muriana and Klaenhammer 1991; Zamfir 
et  al. 1999). In addition, no decrease on antimicrobial 
activity was observed for bacteriocin extract in the pres-
ence of β-mercaptoethanol. This result suggests that 
the activity was not related to the presence of disulfide 
bridges. These are characteristic of class II bacteriocins, 
since its contains at least two cysteines in their compo-
sition that forms a bond (Ennahar et al. 2000). Disulfide 
bridges have been described in some Lactobacillus spp., 
such as L. curvatus (Tichaczek et al. 1993), L. plantarum 
(Ennahar et al. 1996) and L. sake (Schillinger and Lücke 
1989), among others. Further studies may be carried out 
that include cloning, expression and isolation in vector 
and host microorganism in order to elucidate about its 
function.
In parallel, we conducted antimicrobial tests to access 
the bacteriocin extract bioactivity against several uro-
genital pathogens. Bacteriocin extract was shown to 
inhibit the growth of the indicator strain, Gram-positive 
(Gardnerella vaginalis and Streptococcus agalactiae) and 
Gram-negative bacteria Pseudomonas aeruginosa. How-
ever, no antimicrobial effect was observed against the 
enrolled strains of Escherichia coli, Staphylococcus aureus 
and Candida albicans. This finding was not unexpected 
as bacteriocins act mainly against the closely related spe-
cies, while against fungi, the lactobacilli activity, if at all 
present, is probably related with different antimicrobial 
effects, like competition for adhesion sites. Similar results 
were observed in another published study (Mitra et  al. 
2005), while it has been described that bacteriocins pro-
duced by Lactic acid bacteria (including Lactobacillus) 
are primarily active against Gram-positive bacteria (Heng 
et  al. 2007; Jack et  al. 1995). Moreover, several studies 
have been published regarding bacteriocins produced 
by Lactobacillus acidophilus. For example, Lactobacillus 
acidophilus DSM20079 produced an antimicrobial bac-
teriocin (acidocin D20079) with approximately 6.6  kDa 
that had an inhibitory activity against Lactobacillus 
genus, including Lactobacillus delbrueckii subsp. lac-
tis DSM20076, Lactobacillus bulgaricus DSM20080 and 
Lactobacillus sakei NCDO2714, but no evident activ-
ity was observed against other pathogens (Deraz et  al. 
2005). Furthermore, it has been also described by other 
authors that active bacteriocins produced by Lacto-
bacillus acidophilus, are small peptides with different 
physicochemical properties. In fact, for Lactobacillus 
acidophilus JCM1132 a heat-stable two-component bac-
teriocin (J1132) exhibiting a narrow inhibitory activ-
ity against non-pathogenic strains has been described 
(Tahara et al. 1996), and a bacteriocin with 3.1 kDa active 
against pathogenic strains was identified for Lactobacil-
lus acidophilus ATCC4356 (Han et al. 2002).
These results corroborate the LaKS400 probiotic effi-
cacy in vaginal application or its use in other pathologies. 
In fact, this study reports for the first time a new bacte-
riocin produced by LaKS400, with an expected size of 
7.5 kDa and antimicrobial activity against vaginal patho-
gen microorganisms, specifically Gardnerella vaginalis 
Table 2 Inhibitory spectrum of antimicrobial bacteriocin produced by Lactobacillus acidophilus KS400 against indicator 
strain and pathogenic microorganisms
a Indicator microorganism
Microorganisms Source Growth condition Inhibition
Lactobacillus delbrueckii  ATCC9649a Collection MRSB, 37 °C, 10%  CO2 +
Gardnerella vaginalis 586876 Clinical NYCIIIB, 37 °C, 10%  CO2 +
Gardnerella vaginalis 563765 Clinical NYCIIIB, 37 °C, 10%  CO2 +
Gardnerella vaginalis 568799 Clinical NYCIIIB, 37 °C, 10%  CO2 +
Staphylococcus aureus ATCC6538 Collection TSB, 37 °C, aerobic −
Streptococcus agalactiae 181324 Clinical BHIB, 37 °C, aerobic +
Streptococcus agalactiae 179954 Clinical BHIB, 37 °C, aerobic +
Pseudomonas aeruginosa ATCC15442 Collection TSB, 37 °C, aerobic +
Escherichia coli ATCC8739 Collection TSB, 37 °C, aerobic −
Candida albicans ATCC10231 Collection BHIB, 37 °C, aerobic −
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and Streptococcus agalactiae, two most relevant patho-
gens related to vaginal infections. These results corrobo-
rate a new mechanism of action for this probiotic strain 
and support its use in clinical practice for the treatment 
and prevention of vaginal infections. Further studies may 
be carried out to improve bacteriocin production, isola-
tion, purification and elucidate about its possible mecha-
nism of action.
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